Equities

10X Genomics Inc

0A88:LSE

10X Genomics Inc

  • Price (USD)18.50
  • Today's Change0.7272 / 4.09%
  • Shares traded3.51k
  • 1 Year change25.72%
  • Beta2.2414
Data delayed at least 20 minutes, as of Feb 06 2026 17:22 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year 10X Genomics Inc had relatively flat revenues (618.73m to 610.79m), though the company grew net income from a loss of 255.10m to a smaller loss of 182.63m. A reduction in the cost of goods sold as a percentage of sales from 33.85% to 32.09% was a component in the net income growth despite flat revenues.
Gross margin68.90%
Net profit margin-11.89%
Operating margin-14.22%
Return on assets-7.77%
Return on equity-10.12%
Return on investment-9.00%
More ▼

Cash flow in USDView more

In 2024, 10X Genomics Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 10.91m or 1.79% of revenues. In addition the company generated 6.66m in cash from operations while cash used for investing totalled 32.63m.
Cash flow per share-0.3354
Price/Cash flow per share--
Book value per share6.20
Tangible book value per share5.66
More ▼

Balance sheet in USDView more

10X Genomics Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio4.48
Quick ratio4.06
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.